-- Presentation is entitled: Induced ketosis in mild to moderate Alzheimer's disease
BROOMFIELD, Colorado, Feb. 20, 2015 /PRNewswire/ -- Accera, Inc, a leader in the development of new therapies to treat neurological disorders, today announced that Dr. Samuel Henderson, Accera's Vice President of Research and Development, will present a review of the company's technology at the 249th American Chemical Society National Meeting that will be held in Denver, Colorado, March 22-26, 2015.
The presentation entitled, "Induced ketosis in mild to moderate Alzheimer's disease" will take place in the Colorado Biotechnology Session at 10:10-10:50am on Sunday, March 22nd in the Mt. Sopris Room at the Grand Hyatt Denver.
About Accera
Accera is a privately held biotechnology company focused on the development of therapies for central nervous system disorders. Accera's proprietary scientific platform includes breakthrough discoveries focused on addressing brain health and Alzheimer's disease. Accera is leveraging the latest scientific knowledge and understanding of neurological disorders to develop therapies intended to address Alzheimer's disease and other neurological disorders. Accera has world-leading capabilities in clinical development for Alzheimer's disease and applies these strengths to its novel pipeline. The company is developing a pipeline of innovative products targeting several neurodegenerative conditions. Our lead product candidate, AC-1204, a first-in-class ketosis-inducing compound, is being studied in patients with Alzheimer's disease.
CONTACT:
Courtney Settle
Accera, Inc.
Tel: +1-303-999-3700
Email: csettle@accerapharma.com
